2000-2019年84个国家重度抑郁症治疗覆盖率的全球差距:系统综述与贝叶斯Meta回归分析
该研究系统检索2000年1月1日至2021年11月26日PubMed和Embase文献,纳入149项基于人群调查的研究,采用贝叶斯Meta回归分析重度抑郁症治疗覆盖率。结果显示,高收入地区卫生服务使用治疗覆盖率为51%,低及中低收入地区为20%;精神卫生服务使用覆盖率分别为33%和8%;最低充分治疗率分别为23%和3%。作者指出低及中低收入国家数据不足是主要方法学局限。
要点
- 高收入地区重度抑郁症卫生服务使用治疗覆盖率为51%,低及中低收入地区为20%。
- 高收入地区精神卫生服务使用覆盖率为33%,低及中低收入国家为8%。
- 高收入国家最低充分治疗率为23%,低及中低收入国家为3%。
核心结论
- 全球许多地区重度抑郁症治疗覆盖率仍较低,尤其是低及中低收入国家。
- 需要持续开展常规数据收集,以帮助获得更准确的全球治疗覆盖率估计。
研究设计与样本
- 系统综述与贝叶斯Meta回归分析,检索PubMed和Embase中2000年1月1日至2021年11月26日的文献。
- 纳入报告过去12个月或更短时间内重度抑郁症治疗率、或可计算该率及95%不确定性区间的队列和横断面研究。
- 纳入基于人群的调查,代表所研究社区、国家或地区,并使用既定诊断标准诊断重度抑郁症。
- 共纳入149项研究进行定量分析。
- 治疗率采用贝叶斯Meta回归建模,并调整年龄、性别、治疗类型、地点和重度抑郁症评估工具选择等协变量。
主要发现
- 卫生服务使用治疗覆盖率:高收入地区为51%[95% UI 20%,82%],低及中低收入地区为20%[95% UI 1%,53%]。
- 精神卫生服务使用治疗覆盖率:高收入地区为33%[95% UI 8%,66%],低及中低收入国家为8%[95% UI <1%,36%]。
- 最低充分治疗率:高收入国家为23%[95% UI 2%,55%],低及中低收入国家为3%[95% UI <1%,25%]。
局限性
- 主要方法学局限是缺乏来自低及中低收入国家的足够数据,导致无法提供更详细的治疗率估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment coverage for major depressive disorder (MDD) is low in many parts of the world despite MDD being a major contributor to disability globally. Most existing reviews of MDD treatment coverage do not account for potential sources of study-level heterogeneity that contribute to variation in reported treatment rates. This study aims to provide a comprehensive review of the evidence and analytically quantify sources of heterogeneity to report updated estimates of MDD treatment coverage and gaps by location and treatment type between 2000 and 2019. METHODS AND FINDINGS: A systematic review of the literature was conducted to identify relevant studies that provided data on treatment rates for MDD between January 1, 2000, and November 26, 2021, from 2 online scholarly databases PubMed and Embase. Cohort and cross-sectional studies were included if treatment rates pertaining to the last 12 months or less were reported directly or if sufficient information was available to calculate this along with 95% uncertainty intervals (UIs). Studies were included if they made use of population-based surveys that were representative of communities, countries, or regions under study. Studies were included if they used established diagnostic criteria to diagnose cases of MDD. Sample and methodological characteristics were extracted from selected studies. Treatment rates were modeled using a Bayesian meta-regression approach and adjusted for select covariates that quantified heterogeneity in the data. These covariates included age, sex, treatment type, location, and choice of MDD assessment tool. A total of 149 studies were included for quantitative analysis. Treatment coverage for health service use ranged from 51% [95% UI 20%, 82%] in high-income locations to 20% [95% UI 1%, 53%] in low- and lower middle-income locations. Treatment coverage for mental health service use ranged from 33% [95% UI 8%, 66%] in high-income locations to 8% [95% UI <1%, 36%] in low- and lower middle-income countries. Minimally adequate treatment (MAT) rates ranged from 23% [95% UI 2%, 55%] in high-income countries to 3% [95% UI <1%, 25%]) in low- and lower middle-income countries. A primary methodological limitation was the lack of sufficient data from low- and lower middle-income countries, which precluded our ability to provide more detailed treatment rate estimates. CONCLUSIONS: In this study, we observed that the treatment coverage for MDD continues to be low in many parts of the world and in particular in low- and lower middle-income countries. There is a continued need for routine data collection that will help obtain more accurate estimates of treatment coverage globally.
引用
- Moitra M, Santomauro D, Collins PY, et al. The global gap in treatment coverage for major depressive disorder in 84 countries from 2000-2019: A systematic review and Bayesian meta-regression analysis. PLoS Med. 2022. PMID: 35167593. doi:10.1371/journal.pmed.1003901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。